ValiRx raises £1.16M at steep discount, shares drop 17%
What's the deal? ValiRx, the London-listed life sciences group focused on cancer therapeutics and animal health, has raised £1.16M through a share placing at a 17% discount to its market price. The fundraise is intended to support the company's ongoing work in cancer drug development and its expansion into the animal health sector.
Why now? The company appears to need capital to advance its pipeline and fund its push into animal health — a growing adjacent market for life sciences firms looking to diversify revenue streams.
What could go wrong? The steep discount signals weak investor demand and immediately dilutes existing shareholders. ValiRx's share price fell 17% on the news, reflecting market concern about the terms. Small-cap biotech firms raising capital at significant discounts often face a vicious cycle: each dilutive raise can erode confidence, making future fundraising harder and more expensive.
The signal: Small life sciences companies continue to struggle to raise money on favourable terms, especially those still in early clinical stages without significant revenue. The willingness to accept a 17% discount underscores how tough the funding environment remains for pre-revenue biotech firms on London's junior markets.
Read more: proactiveinvestors.co.uk
